China Historical Financial Ratios

SXTC Stock  USD 0.43  0.05  10.42%   
China SXT is presently reporting on over 92 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 15.26, Invested Capital of 0.0, Average Payables of 1.8 M or Stock Based Compensation To Revenue of 0.17 will help investors to properly organize and evaluate China SXT Pharmaceuticals financial condition quickly.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About China Financial Ratios Analysis

China SXT PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate China SXT investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on China financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across China SXT history.

China SXT Financial Ratios Chart

At present, China SXT's Inventory Turnover is projected to increase slightly based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 1.43, whereas Price To Sales Ratio is forecasted to decline to 0.71.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing China SXT Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on China SXT sales, a figure that is much harder to manipulate than other China SXT Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.
Most ratios from China SXT's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into China SXT Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
At present, China SXT's Inventory Turnover is projected to increase slightly based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 1.43, whereas Price To Sales Ratio is forecasted to decline to 0.71.
 2021 2022 2023 2024 (projected)
Days Sales Outstanding689.27248.91254.83327.46
PTB Ratio0.350.130.10.0982

China SXT fundamentals Correlations

1.0-0.330.940.550.320.630.471.00.42-0.750.72-0.190.630.150.070.790.280.940.990.90.59-0.990.030.690.81
1.0-0.360.930.530.370.650.471.00.4-0.720.73-0.180.620.140.070.790.290.931.00.910.6-1.00.030.690.8
-0.33-0.36-0.020.30.16-0.44-0.4-0.36-0.020.43-0.15-0.27-0.720.31-0.310.0-0.17-0.02-0.39-0.3-0.130.440.32-0.34-0.62
0.940.93-0.020.710.490.450.470.930.5-0.580.79-0.160.330.130.070.770.391.00.910.820.63-0.890.030.560.59
0.550.530.30.710.33-0.10.290.530.35-0.30.39-0.010.010.08-0.050.460.40.730.490.440.28-0.480.160.120.2
0.320.370.160.490.330.170.270.370.20.370.60.1-0.36-0.060.00.370.420.470.380.330.37-0.320.040.07-0.14
0.630.65-0.440.45-0.10.170.190.65-0.28-0.490.5-0.240.60.170.020.72-0.120.450.670.830.03-0.670.040.820.7
0.470.47-0.40.470.290.270.190.470.34-0.270.540.410.21-0.380.40.00.920.470.470.360.41-0.46-0.410.360.39
1.01.0-0.360.930.530.370.650.470.4-0.720.73-0.180.620.140.070.790.290.931.00.910.6-1.00.030.690.8
0.420.4-0.020.50.350.2-0.280.340.4-0.280.360.10.04-0.160.240.060.430.490.380.00.91-0.37-0.27-0.110.15
-0.75-0.720.43-0.58-0.30.37-0.49-0.27-0.72-0.28-0.310.23-0.84-0.15-0.1-0.520.01-0.6-0.7-0.65-0.320.750.03-0.63-0.87
0.720.73-0.150.790.390.60.50.540.730.36-0.310.270.11-0.290.540.580.470.770.710.670.5-0.69-0.440.340.5
-0.19-0.18-0.27-0.16-0.010.1-0.240.41-0.180.10.230.27-0.28-0.980.77-0.350.54-0.18-0.21-0.25-0.070.18-0.84-0.39-0.14
0.630.62-0.720.330.01-0.360.60.210.620.04-0.840.11-0.280.240.010.43-0.120.350.640.60.22-0.690.070.60.9
0.150.140.310.130.08-0.060.17-0.380.14-0.16-0.15-0.29-0.980.24-0.760.31-0.490.150.170.220.03-0.130.860.310.1
0.070.07-0.310.07-0.050.00.020.40.070.24-0.10.540.770.01-0.76-0.070.370.060.06-0.020.21-0.07-0.97-0.290.28
0.790.790.00.770.460.370.720.00.790.06-0.520.58-0.350.430.31-0.07-0.160.770.790.860.28-0.780.20.590.6
0.280.29-0.170.390.40.42-0.120.920.290.430.010.470.54-0.12-0.490.37-0.160.380.280.130.41-0.26-0.410.080.06
0.940.93-0.021.00.730.470.450.470.930.49-0.60.77-0.180.350.150.060.770.380.910.820.62-0.890.050.560.61
0.991.0-0.390.910.490.380.670.471.00.38-0.70.71-0.210.640.170.060.790.280.910.910.6-1.00.050.690.81
0.90.91-0.30.820.440.330.830.360.910.0-0.650.67-0.250.60.22-0.020.860.130.820.910.24-0.910.140.820.77
0.590.6-0.130.630.280.370.030.410.60.91-0.320.5-0.070.220.030.210.280.410.620.60.24-0.57-0.190.080.36
-0.99-1.00.44-0.89-0.48-0.32-0.67-0.46-1.0-0.370.75-0.690.18-0.69-0.13-0.07-0.78-0.26-0.89-1.0-0.91-0.57-0.02-0.71-0.83
0.030.030.320.030.160.040.04-0.410.03-0.270.03-0.44-0.840.070.86-0.970.2-0.410.050.050.14-0.19-0.020.3-0.15
0.690.69-0.340.560.120.070.820.360.69-0.11-0.630.34-0.390.60.31-0.290.590.080.560.690.820.08-0.710.30.61
0.810.8-0.620.590.2-0.140.70.390.80.15-0.870.5-0.140.90.10.280.60.060.610.810.770.36-0.83-0.150.61
Click cells to compare fundamentals

China SXT Account Relationship Matchups

China SXT fundamentals Accounts

201920202021202220232024 (projected)
Price To Sales Ratio2.685.542.240.960.750.71
Ptb Ratio1.471.660.350.130.10.0982
Days Sales Outstanding752.83593.38689.27248.91254.83327.46
Book Value Per Share760.38554.56394.9155.0316.0615.26
Free Cash Flow Yield0.0381(0.0532)0.0353(0.08)(1.34)(1.28)
Operating Cash Flow Per Share75.56(45.74)6.45(0.3)(2.22)(2.11)
Capex To Depreciation1.230.270.20.280.03480.033
Pb Ratio1.471.660.350.130.10.0982
Ev To Sales2.572.76(2.94)(5.94)(4.14)(3.93)
Free Cash Flow Per Share42.67(48.98)4.95(0.57)(2.23)(2.34)
Inventory Turnover2.382.752.251.332.912.54
Net Income Per Share(832.08)(95.48)(137.92)(22.23)(3.57)(3.75)
Days Of Inventory On Hand132.54161.91274.98125.47215.03136.18
Payables Turnover1.271.330.911.121.071.43
Capex To Revenue0.07880.01950.0240.03580.0036620.003479
Cash Per Share589.37463.24373.2665.0613.9213.22
Pocfratio14.82(20.11)21.7(23.44)(0.75)(0.71)
Interest Coverage1.28(1.36)(23.78)(11.76)(4.62)(4.39)
Capex To Operating Cash Flow0.44(0.0707)0.23(0.88)(0.003663)(0.00348)
Pfcf Ratio26.25(18.79)28.29(12.5)(0.74)(0.78)
Days Payables Outstanding288.18274.3400.55325.43339.77237.1
Income Quality(0.0908)0.48(0.0468)0.01360.620.53
Roe(1.09)(0.17)(0.35)(0.4)(0.22)(0.21)
Ev To Operating Cash Flow14.22(10.02)(28.53)145.114.143.93
Pe Ratio(1.35)(9.64)(1.02)(0.32)(0.46)(0.44)
Return On Tangible Assets(0.48)(0.0797)(0.17)(0.2)(0.13)(0.14)
Ev To Free Cash Flow25.18(9.36)(37.2)77.384.134.33
Earnings Yield(0.74)(0.1)(0.99)(3.14)(2.15)(2.26)
Intangibles To Total Assets0.0023060.0013260.0011559.43E-48.26E-47.85E-4
Net Debt To E B I T D A0.567.182.672.614.014.21
Current Ratio2.471.61.251.311.351.19
Tangible Book Value Per Share756.33552.97393.9854.9216.0415.24
Receivables Turnover0.480.620.531.471.431.21
Graham Number3.8K1.1K1.1K165.935.9334.13
Shareholders Equity Per Share760.38554.56394.9155.0316.0615.26
Debt To Equity0.02730.720.002720.230.170.26
Capex Per Share32.893.231.50.260.0081430.007735

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.426
Earnings Share
(3.57)
Revenue Per Share
2.223
Quarterly Revenue Growth
0.295
Return On Assets
(0.05)
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.